An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost

Table 2

Study characteristics.

Study	𝑁 (pts)	HB target (g/dL)	ESA	GFR range (mL/min/1.73 m^2)	Primary endpoint	𝑃 value for primary endpoints
CHOIR (2006) [10]	603	13.5 versus 11.3	Epoetin Alfa	15–50	Death, MI, CHF, CVA	0.03 for composite favoring lower Hb
CREATE (2006) [22]	1432	13–15 versus 10.5–11.5	Epoetin Beta	15–35	Composite of 8 CV events, CKD progression	NS for CV events.; 0.03 for ESRD favoring lower Hb group
TREAT (2009) [23]	4038	13 versus 9	Darbepoetin Alfa	20–60	Death, CV Event, ESRD	NS